Introduction
Caused by the bacillus Mycobacterium tuberculosis, tuberculosis (TB) is an infectious disease that typically affects the lungs (pulmonary TB) and is fatal if untreated (Centers for Disease Control and Prevention, 2011) . TB is one of the top ten causes of death worldwide (World Health Organization, 2017) . In 2016, there were an estimated 10.4 million new TB cases. Of those cases, approximately one million were children. People infected with HIV, as well as other immunocompromised individuals, are especially susceptible to TB, and accounted for 0.4 million deaths in 2016. Globally, 1.7 million people died from tuberculosis in 2016 (World Health Organization, 2017) . The recommended treatment for drugsusceptible TB is a six-month regimen starting with two months of four first-line drugs: ethambutol, isoniazid, pyrazinamide and rifampicin (World Health Organization, 2017) . This treatment is associated with significant side effects such as hepatotoxicity, CNS toxicity, exanthema, arthralgia and nausea, which are important factors in lack of compliance (Schaberg et al., 1996) . Although TB treatment has saved millions of lives, the crisis of multidrug-resistant TB (MDR-TB) treatment is a major global health concern. In 2016 there were an estimated 600 000 patients with rifampicin-resistant TB (RR-TB), of which 490 000 had MDR-TB (World Health Organization, 2017) . On top of this, there are drug-drug interactions between anti-HIV drugs and other chronic disease medications for some of the current TB drugs (Koul et al., 2011) . Hence, there is an urgent need for new drug candidates to fight the scourge of TB.
As demonstrated by the action of aminoglycosides, tetracyclines, macrolides, streptogramins and phenicols, interfering with bacterial protein synthesis has been shown to be extremely effective for the development of antibiotics (Kohanski et al., 2010; Wilson, 2014) . Aminoacyl-tRNA synthetases (aaRSs) are a major group of proteins that are essential for protein synthesis. AaRSs catalyze a two-step esterification reaction in which each amino acid (aa) is paired with its cognate tRNA, forming an aminoacyl-tRNA (Ibba & Sö ll, 2000; Sheppard et al., 2008) :
E Á aa$AMP þ tRNA !E þ aa-tRNA þ AMP: ð2Þ
In the first, ATP-dependent step a highly reactive aminoacyl adenylate (aa$AMP) intermediate is formed and an inorganic pyrophosphate is released. In the second step, the amino-acid moiety is transferred from the activated intermediate to the 3 0 -end of the tRNA, yielding an aminoacyl-tRNA as the product and AMP as the leaving group (Ibba & Sö ll, 2000) .
AaRSs have been validated as antimicrobial drug targets (Ochsner et al., 2007; Schimmel et al., 1998) . Anti-aaRS compounds can block the ATP-and/or the amino-acid-binding site, the tRNA-recognition site, an allosteric site or an editing site (Fang, Yu et al., 2015) . The widely used antibiotic mupirocin is in clinical topical use against Staphylococcus aureus infections and binds both the ATP-and isoleucine-binding sites of S. aureus isoleucyl-tRNA synthetase (IleRS; Nakama et al., 2001) . However, M. tuberculosis IleRS is not inhibited by mupirocin and therefore M. tuberculosis is naturally resistant to this antibiotic (Sassanfar et al., 1996) .
Methionyl-tRNA synthetase (MetRS) is particularly interesting since it recognizes both the initiator tRNA f Met and the elongator tRNA Met delivering methionine during translation. Depending on their structural features and conserved motifs, aaRSs can be separated into two classes (Deniziak & Barciszewski, 2001) . MetRS belongs to the class I aaRSs, which are characterized by the amino-acid sequence motifs HIGH and KMSKS and a classical Rossmann fold as part of the catalytic domain. Together with arginyl-, cysteinyl-, isoleucyl-, leucyl-and valyl-tRNA synthetases, MetRS belongs to subclass Ia, with the HIGH and KMSKS motifs corresponding to 18 HVGH 21 and 299 KMSKS 303 in M. tuberculosis MetRS (MtubMetRS). MetRSs can be categorized into two major forms, MetRS1 and MetRS2, depending on structural features and susceptibility to inhibitors. Structurally, MetRS1 orthologs contain one 'knuckle' motif with either one or no Zn 2+ ion bound. MetRS2 enzymes contain two knuckle motifs with either one or two Zn 2+ ions bound. Most Gram-positive bacterial genera harbor the MetRS1 form, while most Gramnegative genera contain the MetRS2 form Green et al., 2009) . A few bacteria harbor both forms Gentry et al., 2003) . Eukaryotic organisms contain both forms, with the mitochondrial enzyme exhibiting MetRS1 features and the cytosolic enzyme being of the MetRS2 form (Green et al., 2009) .
Highly effective compounds that inhibit MetRSs from pathogenic trypanosomatid protozoa have been reported by our group (Pedró -Rosa et al., 2015; Shibata et al., 2011 Shibata et al., , 2012 . These reports focused mainly on MetRS from Trypanosoma brucei, the causative agent of human African trypanosomiasis (HAT), also known as sleeping sickness. Crystal structures of T. brucei MetRS synthetase (TbruMetRS) in complex with various inhibitors Koh et al., 2012 Koh et al., , 2014 Zhang et al., 2016) have guided the design of new antitrypanosomatid compounds with a low nanomolar inhibitory potency on the enzyme and parasites, and a steadily improved pharmacokinetic profile. This series of inhibitors has also been optimized and tested for their effect on MetRS from Staphylococcus aureus (SaurMetRS) and other Gram-positive bacteria, with minimum inhibitory concentrations (MICs) for some compounds of less than 0.02 mg ml À1 (Faghih et al., 2017) .
A major structural biology effort has been made by many investigators to create a platform of crystal structures of key M. tuberculosis proteins to assist in the development of new therapeutic agents to treat tuberculosis patients (e.g. Murillo et al., 2007; Fang, van der Merwe et al., 2015; Terwilliger et al., 2003) . Here, we describe the crystal structure of M. Leishmania major Met-AMP and PP i 206-747 Larson et al. (2011) differences occur compared with M. tuberculosis MetRS, indicating that there are opportunities to arrive at inhibitors which have a higher affinity for the M. tuberculosis enzyme than for the human homologs.
Materials and methods

Expression and purification of MtubMetRS
MtubMetRS was cloned into the AVA0421 vector (Alexandrov et al., 2004; Choi et al., 2011; Mehlin et al., 2006) and expressed in Escherichia coli for subsequent purification. The protein was purified using a Ni-NTA affinity column (Qiagen, Valencia, California, USA) followed by sizeexclusion chromatography (SEC) on a Superdex 75 column (Amersham Pharmacia Biotech) using SEC buffer (20 mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol, 2 mM DTT). The purity of MtubMetRS was assessed by SDS-PAGE and the protein concentration was determined using the Bio-Rad protein-assay dye reagent (Bio-Rad) based on the Bradford method (Bradford, 1976) . A final yield of 1.3 mg pure MtubMetRS per litre of E. coli culture was obtained and the protein was concentrated to about 8 mg ml À1 for crystallization.
Crystallization of MtubMetRS
Purified MtubMetRS was prepared for crystallization by the addition of 10 mM MgATP, 10 mM methionine and 1 mM TCEP (protein solution). Crystals were obtained after one month at room temperature by vapor diffusion using sitting drops equilibrated against a reservoir consisting of 30-34% PEG 8000, 150-200 mM ammonium sulfate, 100 mM sodium cacodylate pH 6.5. The drops consisted of 1 ml MtubMetRS protein solution and 1 ml reservoir solution. After growth, crystals were picked up in a loop (Teng, 1990) , flash-cooled in liquid nitrogen (Haas & Rossmann, 1970) in cryosolution (30% glycerol in reservoir solution) and stored until data collection.
Data collection and structure determination
Data were collected under cryogenic conditions on beamline 12-2 at the Stanford Synchrotron Radiation Lightsource (SSRL) at a wavelength of 0.98 Å . Many crystals exhibited a considerable degree of twinning. Only a single crystal was not twinned and diffracted to a higher resolution than all others. This crystal allowed the eventual structure determination. HKL-2000 (Otwinowski & Minor, 1997) was used for data processing. The structure of M. smegmatis MetRS (Ingvarsson & Unge, 2010; PDB entry 2x1l) was used as a model to obtain initial phases by molecular replacement using Phaser (McCoy et al., 2007) . Iterations of manual building and rebuilding using Coot (Emsley et al., 2010) were alternated with refinement of the structure with REFMAC5 (Murshudov et al., 2011) . MolProbity (Chen et al., 2010) was used throughout the process for structure validation. Data-collection and crystallographic refinement statistics are given in Table 2 . The figures were created with PyMOL (v.1.7; Schrö dinger; https:// www.pymol.org).
Results and discussion
3.1. The structure of the M. tuberculosis MetRSÁMet-AMP binary complex
We solved the structure of M. tuberculosis MetRS (Mtub-MetRS), a 58 kDa monomeric enzyme, in complex with its intermediate product methionyl adenylate (Met-AMP). Despite major efforts, no co-crystals of MtubMetRS in complex with our available MetRS inhibitors could be obtained. The purified enzyme was incubated with the substrates methionine and ATP prior to setting up crystallization trays. The electron-density map revealed the presence of Met-AMP in the active site of the enzyme. The Mtub-MetRSÁMet-AMP complex crystal structure, where the symbol 'Á' indicates a noncovalent complex, was determined at 2.6 Å resolution (Table 2 ). There is one molecule in the asymmetric unit and, except for the final ten residues at the C-terminus, every residue could be built into well defined electron density. Several structural elements can be distinguished in Mtub-MetRS ( Fig. 1) : (i) a Rossmann-fold catalytic domain (CD) with (ii) an inserted connective peptide domain (CP), (iii) a stem-contact fold domain (SCF) containing the conserved KMSKS motif and (iv) an anticodon-binding domain (ABD). The SCF and ABD are connected by a linking 1-helix between helices 14 and 15.
The MtubMetRS CD is predominantly an / domain that extends from the N-terminal end of the protein to residue His290 and is interrupted by the CP, which comprises residues Ile116-Tyr226. The CP comprises two subdomains: subdomain CP1 formed by the antiparallel -strands 4 and 8, and subdomain CP2 formed by helices 5 and 6. Subdomain CP1 in MtubMetRS is in the closed conformation, as seen previously in the structure of MsmeMetRS and other MetRS structures (Ingvarsson & Unge, 2010) . CP1 harbors one 'knuckle' devoid of residues able to coordinate Zn 2+ , which identifies MtubMetRS as a member of the MetRS1 form Green et al., 2009) .
The SCF connects the CD and ABD. The SCF harbors the KMSKS loop which contains, using M. tuberculosis sequence numbering, the conserved motif 299 KMSKS 303 . Interestingly, when superimposing the MtubMetRS structure with the structure of the homologous M. smegmatis MetRS (Msme-MetRS), which shares 76% sequence identity overall and 94% identity in the Met-AMP-binding site, the KMSKS loop adopts dramatically different conformations in these two closely related tRNA synthetases. The KMSKS loop in Regarding tRNA Met binding, the mainly helical ABD of MtubMetRS superimposes with an r.m.s.d. of 1.00 Å for the C atoms onto the equivalent domain of Aquifex aeolicus MetRS (AaeoMetRS) in complex with tRNA Met (PDB entry 2ct8; Nakanishi et al., 2005) . Four out of the five residues, Asn353, Arg357, Trp422, Leu491 and Phe492, that are involved in the recognition of the anticodon triplet 34 CAU 36 of tRNA Met in AaeoMetRS are conserved in MtubMetRS (Asn357, Arg361, Trp431, Val506 and Phe507, respectively), while Leu491 of the mycobacterial enzyme is very similar to Val506 of AaeoMetRS. Therefore, tRNA Met anticodon recognition by MtubMetRS is expected to be similar to that by AaeoMetRS (Fig. 3) .
Interactions of MtubMetRS with Met-AMP
Methionine and ATP were essential for obtaining MtubMetRS crystals. Their reaction led to the formation of Met-AMP, which was bound to the active site of the enzyme, as seen in the electron-density map (Fig. 4a ). Two pockets can be defined in the active site: the methionine-binding pocket (MBP), where the methionyl group of Met-AMP is situated, and the adenine-binding pocket (ABP), where the adenine moiety of Met-AMP binds (Fig. 4b) . Fig. 5 summarizes the MtubMetRS residues binding to the methionyl, phosphoryl, ribosyl and adenylyl groups of Met-AMP, along with a sequence alignment with the MetRSs from other species mentioned in this paper. Most of the interactions between the Met-AMP methionyl group and the enzyme in the MBP are hydrophobic and are mediated by Ala9, Trp228, Ala231, Leu232, Tyr235, Ile264 and His268. The N atom of the methionyl moiety makes hydrogen bonds to the carbonyl of Ile10 and to the side-chain carboxylate of Asp49. One O atom of the phosphoryl group of Met-AMP forms hydrogen bonds to the main-chain amino group of Tyr12 as well as to the imidazole ring of His21. The MtubMetRS residues that form hydrogen bonds to the ribose ring are Glu24, Gly261 and Asp263. Specifically, the 3 0 -hydroxyl group of the ribose is engaged in hydrogen bonds to the carboxylate of Glu24 and to the main-chain amino group of Gly261. At the same time, the 2 0 -hydroxyl hydrogen-bonds to the carboxylate of Asp263. In the ABP, the N 7 atom of the Met-AMP adenine moiety interacts with the imidazole ring of residue His18, while the N 1 and N 6 atoms are engaged in hydrogen bonds to the Leu293 main-chain carbonyl and amino groups, respectively. Addi-tionally, Gly20 and Phe292 make hydrophobic contacts with the Met-AMP adenine ring in the ABP.
In summary, extensive interactions, both hydrophobic and hydrophilic (Fig. 4c) , mediate the formation of the MtubMetRSÁMet-AMP complex, with a buried surface area of 919 Å 2 as calculated by PISA (Krissinel & Henrick, 2007) . Fig. 6 shows the temperature-factor (B-factor) distribution for the Met-AMP molecule in the crystal. The methionyl moiety has a lower B factor than the adenosine group of Met-AMP. This might be owing to the fact that the methionyl end of the Met-AMP molecule is better anchored to the protein Comparison of the anticodon-binding domains (ABDs) of A. aeolicus MetRS (AaeoMetRS) and MtubMetRS. MtubMetRSÁMet-AMP is in blue and AaeoMetRSÁMet-AMPÁtRNA Met (PDB entry 2ct8; Nakanishi et al., 2005) is in light green (protein) and yellow (tRNA). Residues involved in the binding of AaeoMetRS to tRNA Met and the anticodon triplet 34 CAU 36 are shown as sticks and labeled. C atoms are colored green (AaeoMetRS) or yellow (tRNA Met ), N atoms blue and O atoms red. By homology, the residues expected to bind tRNA Met in MtubMetRS would be Asn357 in helix 1, Arg361 in helix 15, Trp431 in helix 19 and Val506 and Phe507 at the C-terminal end of MtubMetRS. The labels of secondary-structure elements are those for the MtubMetRSÁMet-AMP crystal structure. than the adenosine end. This idea corresponds with the fact, discussed below, that the side chain of Phe292 near the adenine ring has the highest B factor in the MtubMetRS Met-AMP binding site (Fig. 6 ). Alternatively, it is possible that Met-AMP is not present at full occupancy, but that instead the MtubMetRS crystal used contains a mixture of Mtub-MetRSÁMet-AMP and MtubMetRSÁMet complexes (possibly even with partial occupancy). This might be somewhat similar to the structure of MsmeMetRSÁMetÁadenosine (PDB entry 2x1l; Ingvarsson & Unge, 2010), where the adenosine molecule presents B factors that are more than three times higher than those of the methionine molecule.
The Met-AMP-binding pocket among methionyl-tRNA synthetases
There are a considerable number of MetRS structures with an adenine ring occupying the adenine-binding pocket. Here, we compare adenine binding in a number of pathogen structures and the only human MetRS structure to date: that of the human cytosolic enzyme. Fig. 5 shows the sequence alignment of MtubMetRS with MsmeMetRS (its closest homolog with known structure; Ingvarsson & Unge, 2010) and additional selected MetRS enzymes. Phe292 is the only residue interacting directly with Met-AMP that differs in the two mycobacterial enzymes. The side chain of Phe292 in MtubMetRS exhibits an intriguing difference in conformation with respect to the equivalent Trp294 in MsmeMetRS. While the indole ring of Trp294 adopts an inward conformation ('in') in MsmeMetRSÁMetÁadenosine, resulting in a stacking hydrophobic interaction with the adenine ring (Fig. 7b ) of the adenosine molecule (PDB entry 2x1l; Ingvarsson & Unge, 2010), the phenyl side-chain group of Phe292 is in an 'out' conformation in MtubMetRSÁMet-AMP, with a single atom of Phe292 in contact with the adenine ring at a distance of 3.9 Å . The high B factor of the Phe292 side chain (Figs. 6 and 7a) suggests that the side chain of Phe292 adopts multiple conformations. In the structure of TbruMetRSÁMet-AMP (PDB entry 4eg3; Koh et al., 2012) , the equivalent Trp547 interacts with the adenine ring of Met-AMP with an 'in' conformation ( Fig. 7c ). In the structure of a truncated version of HsapCytoMetRS, comprising residues 221-834, the residue corresponding to Phe292 in MtubMetRS is Tyr586 and its side chain adopts an 'out' conformation ( Fig. 7d) . In several MetRS structures with a filled adenine pocket, a homologous residue corresponding to MtubMetRS Phe292 is present, which in some instances is in an 'in' conformation (for example in AaeoMetRSÁMet-AMPÁtRNA; PDB entry 2ct8) and in other cases is in an 'out' conformation (for example in LmajMetRSÁMet-AMPÁPP i ; PDB entry 3kfl). Hence, the conformation that the residue equivalent to Phe292 in MtubMetRS adopts in related MetRSs is clearly highly vari- Amino-acid sequence alignment of residues forming the Met-AMP-binding and inhibitor-binding pockets in different species. Met-AMP-binding pocket: MBP, methionine-binding pocket; ABP, adenine-binding pocket; P, Met-AMP phosphate-binding site; R, Met-AMP ribose-binding site. Inhibitorbinding pocket: EMP, enlarged methionine pocket; LR, linker region; AP, auxiliary pocket. Residues indicated as part of the inhibitor-binding pocket are predicted to bind the MetRS inhibitors based on previous MetRSÁinhibitor crystal structures [for example, TbruMetRS (Huang et al., 2016 , 2017 Koh et al., , 2014 Zhang et al., 2016) , BmelMetRS (Ojo et al., 2016) and SaurMetRS (PDB entries 4qrd and 4qre)]. OI, percentage overall protein sequence identity; MI, percentage identity for Met-AMP-binding pocket residues; II, percentage identity for inhibitor-binding pocket residues.
Figure 6
Temperature factors of Met-AMP and the catalytic pocket. The MtubMetRS catalytic pocket and Met-AMP are shown colored according to B factors, with cyan corresponding to the lowest and red to the highest values. Of the residues binding Met-AMP in the MtubMetRSÁMet-AMP structure, Phe292 has the highest B factor (around 100 Å 2 ), which corresponds to the high B factors of the adenosyl group of the Met-AMP molecule.
able. The human mitochondrial enzyme presents residue His340 in the same position and it is obviously hard to predict the conformation that this residue could adopt. Nevertheless, the structural and sequence differences near the adeninebinding pocket of MtubMetRS versus the human homologs might be of help in the future development of antituberculosis chemotherapeutics.
M. tuberculosis MetRS versus its human homologs
It is imperative to compare the MtubMetRS structure with those of its human homologs to evaluate the potential for arriving at selective inhibitors. Superposition of MtubMetRS onto the available human cytosolic apo MetRS (Hsap-CytoMetRS) crystal structure (PDB entry 5gl7; H. Y. Cho, H. J. Lee & B. S. Kang, unpublished work) yields an overall r.m.s.d. of 1.26 Å for the C atoms. The C atoms of the catalytic and anticodon-binding domains of these two structures superpose quite well, with r.m.s.d. values of 1.07 and 1.11 Å , respectively. When superposing the catalytic domains of the two structures, the connective peptide CP1 subdomain of MtubMetRS is moved considerably 'downwards' towards the active site, adopting a closed conformation (Fig. 8a) as described before for MsmeMetRS (Ingvarsson & Unge, 2010) , differing from the conformation of CP1 in human cytosolic MetRS and in other MetRSs (Serre et al., 2001; Crepin et al., 2004) . Especially interesting is the fact that the same subdomain changes conformation upon the binding of inhibitors in TbruMetRS (Koh et al., , 2014 Zhang et al., 2016; Huang et al., 2016 Huang et al., , 2017 . In the TbruMetRSÁMet-AMP structure, CP1 is in the closed conformation, similar to that described here for MtubMetRSÁMet-AMP, but it adopts an open conformation when a TbruMetRS inhibitor is bound . In the case of the human apo cytosolic enzyme structure, CP1 is in a much more open conformation (Fig. 8a) . The structural differences regarding CP1 might be exploitable when aiming for selectivity of compounds against MtubMetRS, since CP1 residues could potentially interact with a compound designed to bind specifically to the mycobacterial enzyme, keeping the CP1 knuckle in the open conformation, and thereby prevent catalytic action.
Overall, MtubMetRS and its human mitochondrial (Hsap-MitoMetRS) and cytosolic counterparts are 38 and 26% identical in sequence, respectively, with 78 and 56% identity, respectively, when comparing residues binding Met-AMP in MtubMetRS with those in HsapMitoMetRS and Hsap-CytoMetRS (Fig. 5) . When comparing the available Hsap-CytoMetRS structure with that of MtubMetRS, there is a significant difference between the two enzymes close to the Met-AMP ribose-binding site in MtubMetRS. The homologous segment to helix 1 of MtubMetRS forms two helices in HsapCytoMetRS, 2 and 3 (Figs. 8b, 8c and 9 pocket' (HCEP) harboring four water molecules in Hsap-CytoMetRS (Fig. 8d ). Owing to both the difference in the secondary structure of helix 1 of MtubMetRS versus helices 2 and 3 in HsapCytoMetRS, as well as the positioning of the pocket-filling side chain of residue His21 in MtubMetRS, the bacterial pocket is smaller, harboring one water molecule instead of four (Fig. 8e) . When aligning the bacterial and human sequences, the reason for this difference appears to be the insertion of an extra glycine, Gly286, in the human cytosolic protein, exactly at the connection between the helices (Fig. 9 ). In the case of HsapMitoMetRS, the structure of which is not available, the amino-acid sequence lacks the extra glycine residue present in HsapCytoMetRS between helices 2 and 3. Therefore, the hinge would be expected to be absent, probably resulting in a secondary structure similar to that of helix 1 in MtubMetRS and the concomitant absence of the HCEP pocket in the human mitochondrial enzyme.
Regarding the design of compounds that have higher affinity for tuberculosis MetRS than for the human homologs, it is of interest that in the Met-AMP-binding region of the human cytosolic enzyme one in about every two residues differs from that in MtubMetRS (Fig. 5) . Moreover, the cytosolic enzyme is a MetRS2 enzyme and MtubMetRS is a MetRS1 enzyme. As reported before for SaurMetRS, many compounds inhibiting bacterial MetRS1 are not potent against the human cytosolic enzyme, which belongs to the MetRS2 form (Green et al., 2009) . Specifically, REP8839 was reported to have a selectivity of more than 1 000 000-fold for SaurMetRS over the 27% identical human cytosolic enzyme (Green et al., 2009) . Therefore, differentially targeting MtubMetRS and not the cytosolic enzyme should be readily feasible. This is somewhat different for the human mitochondrial enzyme since the M. tuberculosis and human mitochondrial enzymes both belong to the MetRS1 form. Nevertheless, 22% of the residues forming the Met-AMP-binding site in M. tuberculosis and human mitochondrial MetRS are different, and 24% in the inhibitor-binding site (Fig. 5) . Moreover, compound REP8839 mentioned above has a 1000fold higher affinity for the S. aureus enzyme than for human mitochondrial MetRS (Green et al., 2009) , while the aminoacid difference in the inhibitor-binding site between the S. aureus and human mitochondrial enzymes is 24%, i.e. the same as in the comparison of M. tuberculosis and human mitochondrial MetRS. The fact that considerable selectivity between human mitochondrial and bacterial MetRS enzymes could be achieved in the case of S. aureus is promising and indicates that there are opportunities to arrive at inhibitors that have a higher affinity for the M. tuberculosis MetRS than for both human homologs.
In conclusion, this paper reports the crystal structure of M. tuberculosis MetRS bound to its substrate intermediate. Analysis of the structure reveals differences from the human orthologs that will be useful for designing selective inhibitors in the effort to discover new antituberculosis drugs.
Figure 9
Sequence alignment of the MtubMetRS 1-helix region with those of human MetRS homologs. In HsapCytoMetRS the secondary structure of the region corresponds to two -helices: 2 and 3. The insertion, compared with both MtubMetRS and HsapMitoMetRS, of Gly286 in HsapCytoMetRS is indicated by a red box. Conserved residues are shown on a black background, conservative changes on a gray background and divergent residues on a white background.
